Us Congress 2023-2024 Regular Session

Us Congress House Bill HB8390

Introduced
5/14/24  
Refer
5/14/24  

Caption

Mental Health and MAMA Act of 2024 Mental Health and Making Access More Affordable Act of 2024

Impact

The implications of HB8390 are far-reaching, particularly in how it influences state laws related to health insurance. By effectively eliminating cost-sharing for critical mental health and substance use disorder services for pregnant and postpartum individuals, the bill seeks to promote better maternal mental health. It aims to reduce financial barriers for families, ensuring they can access essential services without worrying about out-of-pocket costs. Additionally, the requirement for coverage extends to telehealth services, which could enhance accessibility, especially for those in remote areas.

Summary

House Bill 8390, titled the 'Mental Health and Making Access More Affordable Act of 2024' (or 'Mental Health and MAMA Act of 2024'), proposes significant amendments to existing laws regarding health insurance coverage. The primary focus of the bill is on the provision of mental health and substance use disorder services during and after pregnancy. Specifically, it mandates that group health plans and health insurance issuers must provide said mental health and substance use disorder services without imposing cost-sharing requirements from the time of pregnancy diagnosis through the one-year period following the conclusion of the pregnancy. This aims to improve access to necessary mental health support for new and expectant mothers.

Contention

Despite its potential benefits, the bill may face opposition. Critics might argue that mandating such comprehensive coverage could increase insurance premiums or place an undue burden on employers that provide health insurance. Additionally, there may be concerns about the specific definitions and scope of mental health and substance use disorder services, particularly how they are applied within different insurance frameworks, such as ERISA and the Internal Revenue Code. The balance between increased access to care and the economic impact on insurance providers and employers will likely be a point of contention in legislative discussions.

Companion Bills

US SB4331

Related Mental Health and MAMA Act of 2024 Mental Health and Making Access More Affordable Act of 2024

Similar Bills

US SB4331

Mental Health and MAMA Act of 2024 Mental Health and Making Access More Affordable Act of 2024

US SB4060

Justice for Incarcerated Moms Act

US SB2846

CARE for Moms Act Community Access, Resources, and Empowerment for Moms Act

US SB3006

SAFE in Recovery Act Substance Use Disorder and Family Engagement in Recovery Act

US HB5568

CARE for Moms Act Community Access, Resources, and Empowerment for Moms Act

US HB685

Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)

US SB3247

Stop Shackling and Detaining Pregnant Women Act

US HB6298

Stop Shackling and Detaining Pregnant Women Act